Amicus Therapeutics, Inc. (FOLD) Social Stream



Amicus Therapeutics, Inc. (FOLD): $7.94

0.18 (+2.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FOLD to Watchlist
Sign Up

Industry: Biotech


Ranked

of 393

in industry

Amicus Therapeutics Inc (FOLD) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering FOLD.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-10 11 $29 $12 $18.333 $9.47 93.59%
2021-11-15 10 $29 $12 $18.444 $9.47 94.76%
2021-11-23 10 $29 $12 $18.555 $9.47 95.93%
2022-01-13 9 $29 $12 $17.375 $9.47 83.47%
2022-01-17 9 $29 $15 $17.875 $9.47 88.75%
2022-01-26 9 $29 $15 $17.5 $9.47 84.79%
2022-02-25 9 $29 $14 $17 $9.47 79.51%
2022-02-28 9 $20 $14 $15.5 $9.47 63.67%

The Trend in the Analyst Price Target


FOLD's average price target has moved down $1.5 over the prior 26 weeks.

FOLD reports an average of 71.04% for its upside potential over the past 47 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-03 10 29 12.5 17.79 10.06 76.84%
2021-07-10 12 29 12.0 16.88 9.62 75.47%
2021-09-04 13 29 13.0 16.90 11.63 45.31%
2021-09-11 13 29 13.0 16.90 10.93 54.62%
2021-11-23 10 29 12.0 17.50 11.33 54.46%

FOLD Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.22 8 0 1 0 0 9

The Trend in the Broker Recommendations


FOLD's average broker recommendation rating improved by 1.4 over the prior 31 weeks.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for FOLD as an investment opportunity.

  • In the context of all US stocks, Amicus Therapeutics Inc's variance in analysts' estimates is lower than -849.89% of them.
  • To contextualize these metrics, consider that out of all US stocks, Amicus Therapeutics Inc's average analyst price target is higher than 213.89% of them.
  • In terms of how Amicus Therapeutics Inc fares relative to Pharmaceutical Products stocks, note that its number of analysts covering the stock is higher than 867.45% of that group.
  • In the context of stocks in the mid market cap category, Amicus Therapeutics Inc's upside potential (average analyst target price relative to current price) is higher than 831.93% of them.

In the Pharmaceutical Products industry, FGEN, EVO, and ESPR are the three stocks most similar to Amicus Therapeutics Inc regarding the price target and analyst recommendation information presented here.

Is FOLD a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8571 seconds.